Discussion  by unknown
Our study had significant limitations. Despite being
the largest study of its kind in the literature, the number
of patients in the study remains relatively small. Our
failure to assign statistical significance to the observed
difference in mortality might therefore be due to insuf-
ficient power. Furthermore, because the study includes
patients operated on by a large number of surgeons
without a rigidly defined institutional philosophy regard-
ing acceptable prosthesis size, details of the decision-
making process regarding ARE are vague. This does not,
however, weaken the empiric observations reported. Fi-
nally, as noted above, our data address only one half of
the risk– benefit equation determining the indications for
ARE. With absent data concerning the effect of PPM on
hemodynamic outcome, we cannot argue the place of
ARE in the surgeon’s armamentarium nor justify its use
in particular circumstances. Furthermore, we do not have
hemodynamic measures of the effectiveness of posterior
ARE in relieving the outflow gradient. Indeed, one could
argue that the procedure as performed failed to provide
sufficient annular enlargement because valve size re-
mained a predictor of operative mortality. This might in
part be due to inconsistency among surgeons with regard
to extension of the enlargement across the true annulus.
Nonetheless, our data do satisfactorily address the issue
of incremental operative risk imposed by application of
this approach.
We conclude that ARE using the Nicks technique can
be accomplished with low operative risk, and accord-
ingly, surgeons should not be reluctant to do so when
they believe it is otherwise clinically indicated.
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Discussion
Dr David A. Fullerton (Denver, Colo). Dr Dhareshwar, I
would like to compliment you both on a very crisp and clear
presentation and also on an extremely well-written manuscript.
Thank you very much for forwarding that to me, as well as a
copy of your presentation.
I liked your topic, your presentation, and your article in large
part because it fits my bias perfectly. I have to acknowledge that
I have a very low threshold for enlarging the annulus, and
therefore it is pleasing to see your data, particularly in light of
the background literature on the subject.
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Acknowledging that in your analysis the annular enlargement
per se did not fall out as an independent risk factor for perioper-
ative death, small valve size did. I am curious as to what your
insight might be as to why that is the case.
Dr Dhareshwar. In our data set, if you look at the range of
preoperative annulus sizes, almost 60 patients had an annulus
size of less than 19 mm, which means we could not even get the
19-mm valve in place. Even after an ARE, the valve size that we
could implant was 19 mm in almost 43 patients. With the large
proportion of patients having a very small aortic annulus, in our
study that turned out to be a more significant risk factor than
annular enlargement per se.
Dr Fullerton. But according to your article, and I realize I
am taking you beyond the analysis of this talk, among those
who did not have an annular enlargement, there was a substan-
tial percentage who actually received small valves. That led me
to wonder what the indications were, if you know, for actually
enlarging the annulus.
Dr Dhareshwar. I think it all depends on the clinical judg-
ment at the time of the operation. Although everybody tries to
implant the largest valve size possible, and we have in our
minds when we go into the operating room a minimum size
valve we are willing to place, sometimes it is not possible to
enlarge the annulus. Presumably the surgeon believed annular
enlargement was not needed in that particular patient.
Dr Fullerton. Given the fact that this is a retrospective
review, am I safe to assume then that there is no protocol-driven
algorithm for addressing the size of the anticipated implanted
prosthesis as a function of the patient’s body surface area?
Dr Dhareshwar. It is based on the individual surgeon. We
always take into account the general body surface area and how
the patient looks, his age, and the comorbidities. If the life
expectancy is not that long—if we are doing a case on an
85-year-old patient, aortic annular enlargement might not be
needed in that patient. It is a clinical judgment, and I think it has
to be individualized to the patient.
Dr Fullerton. One final question. You indicated on your
conclusion slide that you do not have long-term follow-up, but
the literature would suggest that among patients who are given
an AVR and who are left with an effective orifice area to body
surface area ratio of less than about 0.8 cm2/m2, the classic
definition of PPM, it turns out, to my surprise, that the survival
curves for those 2 situations do not begin to diverge until about
7 or 8 years after the operation. Given the size of your database
and the magnitude of your experience, I am curious to know
whether you have any insight into that.
Dr Dhareshwar. We are working on that. It is one of the
difficulties that we face when we look at the relationship
between an effective orifice area rather than the valve size per
se. Over the period of 9 years from 1993-2001, we had more
than 15 different valves implanted. We have now restricted
ourselves to 3 or 4 valve types, and it will be easier to predict
the effective orifice area based on in vivo Doppler studies. We
did not want to use geometric orifice areas, which we believe
can be misleading. We would prefer to use iEOA based on
Doppler studies in vivo. We hope that given the fewer valves
that we have used over the last 8 to 10 years or so, in a couple
of years we should have long-term data in these patients.
Dr Fullerton. Thank you very much.
Dr Dhareshwar. Thank you.
Dr D. Craig Miller (Stanford, Calif). I have been trying to
scratch the foggy catacombs of my brain, but you called this a
Nicks, and if I remember correctly from 30 years ago, it is not
a Nicks at all. A Nicks is done in the commissure between the
right and the noncoronary sinus, the membranous septum. This
is what most of us would call a hemi-Manouguian. Are there
any historians or old-timers in the room who could clarify that?
Dr Sundt. Craig, there is often confusion on this. Manou-
guian’s enlargement is through the commissure between the left
and noncoronary sinus, and Nicks is at the base of the noncoro-
nary sinus.
Dr Miller. He was an Australian surgeon, right? Okay. I
stand corrected. Thank you. Manouguian does go through the
commissure between the left and noncoronary sinus.
Dr Sundt. Does that go down in the record books at the
Western? (laughter).
Dr Miller. I am wrong 100 times a day. So the Manouguian
is between the commissure between the left and the noncoro-
nary sinus, and the Nicks is right in the belly of the noncoronary
sinus?
Dr Sundt. That is right.
Dr Miller. Okay, I stand corrected, and I think we all stand
smarter.
Dr Sundt. Wait, the president says I am wrong, too. Scott?
Dr Mitchell. I hate to pull rank and disagree with Craig, but
actually, the Manouguian I think stops just through the annulus,
but the Nicks does not go onto the anterior leaflet. It stops
before it goes across the annulus. Therefore this is probably a
combination of the Nicks and Manouguian.
Unidentified speaker. I enjoyed your presentation. When
you analyzed your data, did you look at patients who still had
a residual mismatch after the enlargement, and did you analyze
it with respect to mechanical versus stented tissue valves?
Second, in the era of homografts and stentless tissue valves,
what is your current indication for doing a root enlargement in
these patients?
Dr Dhareshwar. That is an excellent question. Unfortu-
nately, as I said before, we did not have a lot of data on the
effective orifice areas, given more than 15 different valve types,
and therefore we did not look at existing or residual PPM in
these patients, but we hope that in subsequent studies we can
look at that. There is no difference between the bioprosthesis
and the mechanical valves.
Regarding homografts and stentless valves, our bias is to-
ward performing root enlargement preferentially over stentless
valves. We currently use homografts in the pediatric population
and in adults only if we are faced with the situation of endo-
carditis. Very rarely do we use stentless valves when we think
that the patient needs a root replacement for aneurysm on
dissection rather than just an AVR, and therefore we are biased
toward a root enlargement and getting in a larger valve than
using stentless valves.
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Dr Benjamin Youdelman (Philadelphia, Pa). In your study
you looked at 15 different types of valves. The data I am
presenting at this meeting comparing 8 common valves shows
a range of 1.5 to 0.5 mm between the measured size and the
labeled valve size, and I suspect there would be a similar range
over your 15 different valves. I would argue that your analysis
should not be done using labeled valve size but that you should
use geometric orifice area. I would also argue that effective
orifice area should not be used because of the variability in
measurements that is likely caused by differences in heart rate,
blood pressure, ventricular function, and echocardiographic
data acquisition.
Dr Dhareshwar. I agree with your comments. I also had a
look at your poster. It is a nice poster.
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